PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21562974-5	2011	LV-IS-reduction induced by esmolol + milrinone was eliminated in the presence of protein kinase A-(PKA)-inhibitor (Rp-cAMPS) or Akt-inhibitor (AKT 1/2 kinase inhibitor).	Milrinone	37-46	AKT serine/threonine kinase 1	Rattus norvegicus	128-131	
21562974-5	2011	LV-IS-reduction induced by esmolol + milrinone was eliminated in the presence of protein kinase A-(PKA)-inhibitor (Rp-cAMPS) or Akt-inhibitor (AKT 1/2 kinase inhibitor).	Milrinone	37-46	AKT serine/threonine kinase 1	Rattus norvegicus	143-146	
21562974-7	2011	This cell protective effect by esmolol + milrinone was abrogated in the presence of PKA-inhibitor or Akt-inhibitor.	Milrinone	41-50	AKT serine/threonine kinase 1	Rattus norvegicus	101-104	
21562974-14	2011	CONCLUSIONS: Late-ischemia/early reperfusion therapy with esmolol + milrinone additively reduces LV-IS associated with robust activation of myocardial PKA and subsequent Akt-antiapoptotic pathway.	Milrinone	68-77	AKT serine/threonine kinase 1	Rattus norvegicus	170-173